Related references
Note: Only part of the references are listed.Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Marc Hafner et al.
NATURE METHODS (2016)
Managing risks in drug discovery: reproducibility of published findings
Aimo Kannt et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2016)
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai et al.
ONCOTARGET (2016)
Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function
Andre Kleensang et al.
SCIENTIFIC REPORTS (2016)
Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells
John P. Vanden Heuvel et al.
ELIFE (2016)
Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models
Paul Geeleher et al.
GENOME BIOLOGY (2016)
Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation
Idun Dale Rein et al.
CELL CYCLE (2015)
PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
Florian Engert et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Jose Luis Ordonez et al.
ONCOTARGET (2015)
Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
Malcolm A. Smith et al.
CLINICAL CANCER RESEARCH (2015)
Initial Testing (Stage 1) of the PARP Inhibitor BMN 673 by the Pediatric Preclinical Testing Program: PALB2 Mutation Predicts Exceptional In Vivo Response to BMN 673
Malcolm A. Smith et al.
PEDIATRIC BLOOD & CANCER (2015)
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma
Sonja J. Gill et al.
PLOS ONE (2015)
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
Edwin Choy et al.
BMC CANCER (2014)
Refinement of Experimental Design and Conduct in Laboratory Animal Research
Jeremy D. Bailoo et al.
ILAR JOURNAL (2014)
NIH to balance sex in cell and animal studies
Janine A. Clayton et al.
NATURE (2014)
Preclinical Evaluation of the PARP Inhibitor, Olaparib, in Combination With Cytotoxic Chemotherapy in Pediatric Solid Tumors
Robin E. Norris et al.
PEDIATRIC BLOOD & CANCER (2014)
Targeting the DNA Repair Pathway in Ewing Sarcoma
Elizabeth Stewart et al.
CELL REPORTS (2014)
An open investigation of the reproducibility of cancer biology research
Timothy M. Errington et al.
ELIFE (2014)
Effects of hypoxia on human cancer cell line chemosensitivity
Sara Strese et al.
BMC CANCER (2013)
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Britta Stordal et al.
MOLECULAR ONCOLOGY (2013)
Power failure: why small sample size undermines the reliability of neuroscience
Katherine S. Button et al.
NATURE REVIEWS NEUROSCIENCE (2013)
PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
J. Chad Brenner et al.
CANCER RESEARCH (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
Atmospheric Oxygen Inhibits Growth and Differentiation of Marrow-Derived Mouse Mesenchymal Stem Cells via a p53-Dependent Mechanism: Implications for Long-Term Culture Expansion
Siddaraju V. Boregowda et al.
STEM CELLS (2012)
Guidelines for accurate EC50/IC50 estimation
J. L. Sebaugh
PHARMACEUTICAL STATISTICS (2011)
Replication in Prevention Science
Jeffrey C. Valentine et al.
PREVENTION SCIENCE (2011)
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
Victoria J. Weston et al.
BLOOD (2010)
Conducting Meta-Analyses in R with the metafor Package
Wolfgang Viechtbauer
JOURNAL OF STATISTICAL SOFTWARE (2010)
The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?
Peyton Hughes et al.
BIOTECHNIQUES (2007)
Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma
Nicolo Riggi et al.
CANCER RESEARCH (2006)
Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells
N Riggi et al.
CANCER RESEARCH (2005)
Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators
S Batra et al.
CANCER RESEARCH (2004)
Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques
A Martínez-Ramírez et al.
CANCER GENETICS AND CYTOGENETICS (2003)
Share Paper
